loading page

Ligand conjugated lipid-based nanocarriers for cancer theranostics
  • +4
  • Rahul Kumar,
  • Daphika Dkhar S,
  • Rohini Kumari,
  • Supratim Mahapatra,
  • * Divya,
  • Vikash Kumar Dubey,
  • Pranjal Chandra
Rahul Kumar
Indian Institute of Technology BHU Varanasi

Corresponding Author:[email protected]

Author Profile
Daphika Dkhar S
Indian Institute of Technology BHU Varanasi
Author Profile
Rohini Kumari
Indian Institute of Technology BHU Varanasi
Author Profile
Supratim Mahapatra
Indian Institute of Technology BHU Varanasi
Author Profile
* Divya
Indian Institute of Technology BHU Varanasi
Author Profile
Vikash Kumar Dubey
Indian Institute of Technology BHU Varanasi
Author Profile
Pranjal Chandra
Indian Institute of Technology BHU Varanasi
Author Profile

Abstract

Cancer is one of the major health-related issues affecting the population worldwide and subsequently accounts for the second-largest death. Genetic and epigenetic modifications in oncogenes or tumor suppressor genes affect the regulatory systems that lead to the initiation and progression of cancer. Conventional methods, including chemotherapy/radiotherapy/appropriate combinational therapy and surgery, are being widely used for theranostics of cancer patients. Surgery is useful in treating localized tumors, but it is ineffective in treating metastatic tumors, which spread to other organs and result in a high recurrence rate and death. Also, the therapeutic application of free drugs is related to substantial issues such as poor absorption, solubility, bioavailability, high degradation rate, short shelf-life, and low therapeutic index. Therefore, these issues can be sorted out using nano lipid-based carriers (NLBCs) as promising drug delivery carriers. Still, at most, they fail to achieve site targeted drug delivery and detection. This can be achieved by selecting a specific ligand/antibody for its cognate receptor molecule expressed on the cancer cell surface. In this review, we have mainly discussed the various types of ligands used to decorate NLBCs. A list of the ligands used to design nanocarriers to target malignant cells specifically has been extensively undertaken, and the approved ligand decorated lipid-based nanomedicines with their clinical status has been explained in tabulated form to provide a wider scope to the readers regarding ligand coupled NLBCs.
28 Feb 2022Submitted to Biotechnology and Bioengineering
28 Feb 2022Submission Checks Completed
28 Feb 2022Assigned to Editor
28 Feb 2022Reviewer(s) Assigned
13 Apr 2022Review(s) Completed, Editorial Evaluation Pending
13 Apr 2022Editorial Decision: Revise Major
12 May 20221st Revision Received
12 May 2022Submission Checks Completed
12 May 2022Assigned to Editor
12 May 2022Reviewer(s) Assigned
03 Aug 2022Review(s) Completed, Editorial Evaluation Pending
03 Aug 2022Editorial Decision: Accept
11 Aug 2022Published in Biotechnology and Bioengineering. 10.1002/bit.28205